Difference between revisions of "JWH-200"
(Created page with "JWH-200 (WIN 55,225) is an analgesic chemical from the aminoalkylindole family that acts as a cannabinoid receptor agonist. Its binding affinity at the CB1 receptor is 42n...") |
(→See also) |
||
| Line 6: | Line 6: | ||
* [[JWH-018]] | * [[JWH-018]] | ||
* [[JWH-073]] | * [[JWH-073]] | ||
| − | * [[CP | + | * [[CP 47,497]] |
* [[HU-210]] | * [[HU-210]] | ||
* [[A-796,260]] | * [[A-796,260]] | ||
* [[WIN 55,212-2]] | * [[WIN 55,212-2]] | ||
Latest revision as of 03:40, 15 February 2015
JWH-200 (WIN 55,225) is an analgesic chemical from the aminoalkylindole family that acts as a cannabinoid receptor agonist. Its binding affinity at the CB1 receptor is 42nM, around the same as that of THC, but its analgesic potency in vivo was higher than that of other analogues with stronger CB1 binding affinity in vitro, around 3 times that of THC but with less sedative effect, most likely reflecting favourable pharmacokinetic characteristics. It was discovered by, and named after, Dr. John W. Huffman.
The US DEA temporarily declared JWH-200 a schedule I controlled substance on 1 March 2011 through 76 FR 11075, and permanently instated the same schedule on 9 July 2012 in the Section 1152 of the Food and Drug Administration Safety and Innovation Act. As of 26 June 2011, the drug is legal in Canada.
